Live feed07:30:00·60dPRReleasevia QuantisnowImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In SituByQuantisnow·Wall Street's wire, on your screen.IBRX· ImmunityBio Inc.Health Care
